ICER released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) “cost recovery” for the manufacturer, representing an estimate based on peer-reviewed methods of calculating the minimum costs of production for a course of therapy; and 2) traditional cost-effectiveness analyses looking at the incremental health benefits and costs within the health system. The models will be used to track and evaluate any potential future treatments for COVID-19. Click here to learn more about ICER’s adapted methods for assessing pricing during a pandemic.

Interventions of Interest:

  • remdesivir (VEKLURY®)

For questions, please contact Meaghan Cummings at .

Final Documents

Below you will find the final documents from the policy paper review process:

According to our most recent COVID-19 update:

Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the totality of evidence no longer supports an assumption of survival benefit from remdesivir; however, new data from US-based ACTT-1 trial does support savings on insurer payment for hospital services. Given these new data and remdesivir’s expanded label to include less severely ill patients, ICER now suggests a health-benefit price benchmark of $2,470 for hospitalized patients with moderate-to-severe disease, and $70 for patients hospitalized with milder disease.